Building resilience with heart rate variability biofeedback (HRVB) in emergency department and ICU healthcare workers: a randomized controlled trial
Abstract
Healthcare workers in emergency departments (EDs) and intensive care units (ICUs) are highly vulnerable to stress and burnout. Resilience training may mitigate these effects, but most programs are resource intensive and untested. Heart Rate Variability Biofeedback (HRVB) is a brief intervention (30-min introduction and self-practice 10 min twice daily) that shows promise, yet randomized controlled trials are limited. We randomized patient-facing healthcare workers (n = 37) from EDs and ICUs at a large Southwestern medical center to 4 weeks of HRVB or a waitlist (WL) control. After posttreatment assessment, WL participants crossed over to receive HRVB, and both groups were reassessed 4 weeks later. Resilience, stress, depression, and burnout were measured at pretreatment, posttreatment, and follow-up. Consistent with prediction, resilience (CD-RISC-10) increased significantly in the HRVB group relative to WL from pre- to posttreatment (d = .79, p = .003), and gains were maintained at follow-up. Contrary to prediction, reductions in stress, depression, and burnout were not significantly greater in HRVB than WL. Reliable Change Index analysis showed 21% of HRVB participants improved reliably at posttreatment and 24% at follow-up. Findings support HRVB as a feasible, individually delivered intervention to enhance resilience among ED and ICU healthcare providers.
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design. Reported size: 37 participants or records.
Read the paper
Related studies
- The Matrisome: In Silico Definition and In Vivo Characterization by Proteomics of Normal and Tumor Extracellular Matrices
- The Escherichia coli MG1655 in silico metabolic genotype: Its definition, characteristics, and capabilities
- In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling
- In silico prediction of splice-altering single nucleotide variants in the human genome
- In silico clinical trials: how computer simulation will transform the biomedical industry
- In silico optimization of a guava antimicrobial peptide enables combinatorial exploration for peptide design
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.